Latest Talon Therapeutics Inc (TLON) Headlines Ac
Post# of 5
Posted On: 03/11/2014 7:37:27 PM
Latest Talon Therapeutics Inc (TLON) Headlines
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market in the G8 Countries to 2020
M2 - Tue Feb 25, 10:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfrpmb/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering. The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential with increasing incidence rate of the disease across the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types - childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia. The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia incidence rate is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.). In contrast to the growth of the market, the cost of therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020. Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013. Scope of the Report Existing Regimens/Drugs - Hyper-CVAD Regimen - CALGB 8811 Regimen - Linker Regimen - Nucleoside Metabolic Inhibitors (Clolar and Nelarabine) - Oncaspar Pipeline Drugs (Phase III) - Graspa - Marqibo - Inotuzumab Ozogamicin Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Acute Lymphocytic Leukemia Market Dynamics 5 Leukemia Product Market 6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase III) 7 Geographic Analysis 8 Company Profiles - Erytech Pharma - Genzyme Corporation - Glaxosmithkline Plc - Pfizer Inc - Sigma-Tau Pharmaceuticals, Inc - Talon Therapeutics, Inc (Spectrum Pharmaceuticals, Inc) For more information visit http://www.researchandmarkets.com/research/gfrpmb/acute
Research and Markets: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)
Business Wire - Tue Dec 17, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzwbjj/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering.
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)
M2 - Tue Dec 17, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/6skk97/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering. The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials). The acute lymphocytic/lymphoblastic leukemia therapeutics market is valued at an estimated $2,777.2 million in 2013 and is expected to reach $3,780.3 million by 2020, at a CAGR of 4.0% from 2015 to 2020. Presently, the acute lymphocytic/lymphoblastic leukemia market is driven by factors such as the increasing incidence rate of ALL cases, development of innovative therapies such as multi-drug regimens, and continuous efforts of pharmaceutical companies to offer superior-quality drugs. Such improved regimens and drugs have shown significant results in the overall survival rate. The overall growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market is largely challenged by the patent expiration of existing drugs. Arranon (nelarabine), a monotherapy drug, lost its patent in February 2013, whereas, Clolar (clofarabine) is due for patent expiration in 2018. Some of the major players in this market include ERYtech Pharma (France), Talon Therapeutic, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), Pfizer, Inc. (U.S.), and Genzyme Corporation (U.S.). Key Topics Covered: Introduction Executive Summary Market Overview Acute Lymphocytic Leukemia Market Dynamics Leukemia Product Market Acute Lymphocytic Leukemia Pipeline Molecules (Phase III) Geographic Analysis Company Profiles (Overview, Financials, Products Portfolio, Growth Strategy, and Developments)* *Details On Financials, Products Portfolio, Growth Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies. Competitive Developments (2008 - 2013) List of Tables (50 Tables) List of Figures (28 Figures) For more information visit http://www.researchandmarkets.com/research/6skk97/acute About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Lymphocytic Leukemia Therapeutics Market 2020 Forecasts
M2 - Wed Dec 11, 3:27AM CST
The acute lymphocytic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic leukemia may also occur in adults. The acute lymphocytic leukemia market is segmented into two types-childhood acute lymphocytic leukemia and adult acute lymphocytic leukemia.
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Business Wire - Tue Sep 03, 6:00AM CDT
--Two ongoing Phase 3 trials evaluating Marqibo in additional indications.
LQMT, GSAT, TLON and ACTC added to OTC Active Stock Watch List at EPR
ACCESSWIRE - Thu Jul 18, 8:05AM CDT
New York, NY - (ACCESSWIRE) - 07/18/2013 - Equity Profile Report initiates its OTC Active Stock Watch List adding Liquidmetal Technologies Inc. (OTC:LQMT), Globalstar Inc. (OTC:GSAT), Talon Therapeutics, Inc. (OTC:TLON) and Advanced Cell Technology Inc. (OTC:ACTC)
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
GlobeNewswire - Thu Jul 18, 7:00AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that its licensee, Talon Therapeutics, Inc. (OTCBB:TLON), announced that it will be acquired by Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI).
Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.
Business Wire - Wed Jul 17, 6:00AM CDT
--Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion is expected to be launched later this year through Spectrum's existing hematology sales force.
Spectrum Pharmaceuticals Acquires Talon Therapeutics
GlobeNewswire - Wed Jul 17, 6:00AM CDT
Talon Therapeutics, Inc. (OTCQB:TLON) today announced that a subsidiary of Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI) entered into an agreement to purchase approximately 89% of the outstanding shares of Talon (the "Company") directly from the Company's principal stockholders. Spectrum also entered into an agreement with the Company under which the subsidiary of Spectrum will purchase additional shares from the Company that, together with the shares acquired from the Company's principal stockholders, will represent in excess of 90% of the outstanding shares of Talon, and under which Spectrum will acquire the remaining outstanding shares of Company common stock through a "short-form" merger of the subsidiary of Spectrum into the Company. The Company and Spectrum expect that the share purchase and the merger will be completed within one business day.
Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
M2 - Thu Jun 27, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5m9c2h/global_lung) has announced the addition of the "Global Lung Cancer Therapeutics Market 2012-2016" report to their offering. Global Lung Cancer Therapeutics Market To Grow At A CAGR Of 13.26 Percent Over The Period 2012-2016 The Global Lung Cancer Therapeutics Market 2012-2016 report has been prepared based on an in-depth analysis of the market with inputs from industry experts. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''There has been an increase in medical tourism in the APAC region. Patients from all around world are visiting countries such as China and India for treatments. The healthcare facilities in the APAC region are improving, with excellent healthcare providers providing better treatment for diseases such as cancer or any other treatment at a low cost. Thus, the increase in the number of patients coming to China and India for cancer treatment is a growing trend, which is encouraging the he
Talon Therapeutics, Inc. Reports First Quarter 2013 Financial Results
GlobeNewswire - Wed May 15, 4:00PM CDT
Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the three months ended March 31, 2013.
Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial Results
GlobeNewswire - Mon Apr 01, 8:00AM CDT
Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the fourth quarter and year ended December 31, 2012.
Global Leukemia Therapeutics Market 2012-2016: Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG. Dominate the Market
M2 - Thu Mar 28, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnhx5c/global_leukemia) has announced the addition of the "Global Leukemia Therapeutics Market 2012-2016" report to their offering. TechNavio's analysts forecast the Global Leukemia Therapeutics market to grow at a CAGR of 10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Leukemia Therapeutics market has also been witnessing an increase in the number of mergers and acquisitions. However, the delay in cancer diagnosis could pose a challenge to the growth of this market. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''There has been increase in the volume of medical tourism in the APAC region. Patients from all around the world are visiting countries such as China and India for various treatments. Healthcare facilities in the APAC region are improving and there is an excellent range of h
Talon Therapeutics to Host a Conference Call to Report 2012 Financial Results and Business Update on April 1, 2013
GlobeNewswire - Tue Mar 19, 8:00AM CDT
Talon Therapeutics, Inc. (OTCQB:TLON) will host a conference call on Monday, April 1, 2013 at 9:00AM PDT, to discuss 2012 financial results and provide a business update.
Talon Therapeutics Announces Review of Strategic Alternatives
GlobeNewswire - Mon Jan 07, 8:00AM CST
Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced that the Board has authorized a review of strategic alternatives. Goldman Sachs has been engaged to provide financial advisory services. The review of strategic alternatives may lead to a possible transaction, including the merger, business combination, or sale of the company.
Talon Therapeutics Appoints Elizabeth Weatherman to Board of Directors
GlobeNewswire - Fri Jan 04, 8:00AM CST
Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced the appointment of Elizabeth (Bess) Weatherman to the Company's Board of Directors. Ms. Weatherman is a Managing Director of Warburg Pincus and leads the firm's investment activity in the healthcare sector. Warburg Pincus is the majority shareholder of Talon.
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market in the G8 Countries to 2020
M2 - Tue Feb 25, 10:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/gfrpmb/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering. The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential with increasing incidence rate of the disease across the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types - childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia. The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia incidence rate is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.). In contrast to the growth of the market, the cost of therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020. Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013. Scope of the Report Existing Regimens/Drugs - Hyper-CVAD Regimen - CALGB 8811 Regimen - Linker Regimen - Nucleoside Metabolic Inhibitors (Clolar and Nelarabine) - Oncaspar Pipeline Drugs (Phase III) - Graspa - Marqibo - Inotuzumab Ozogamicin Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Acute Lymphocytic Leukemia Market Dynamics 5 Leukemia Product Market 6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase III) 7 Geographic Analysis 8 Company Profiles - Erytech Pharma - Genzyme Corporation - Glaxosmithkline Plc - Pfizer Inc - Sigma-Tau Pharmaceuticals, Inc - Talon Therapeutics, Inc (Spectrum Pharmaceuticals, Inc) For more information visit http://www.researchandmarkets.com/research/gfrpmb/acute
Research and Markets: Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)
Business Wire - Tue Dec 17, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bzwbjj/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering.
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)
M2 - Tue Dec 17, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/6skk97/acute) has announced the addition of the "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - Pipeline Forecast & Market Forecast in G8 Countries (2011 - 2020)" report to their offering. The acute lymphocytic/lymphoblastic leukemia therapeutics market is segmented based on existing regimens and drugs, pipeline drugs, and geography. The existing regimes and drugs market currently includes three regimens (Hyper-CVAD, Linker, and CALGB 8811) and three monotherapy drugs (Oncaspar, Clolar, and Arranon). In addition, three drugs, namely, Graspa (ERYtech Pharma), Marqibo (Talon Therapeutics), and Inotuzumab Ozogamicin (Pfizer, Inc.) are in the pipeline (Phase III clinical trials). The acute lymphocytic/lymphoblastic leukemia therapeutics market is valued at an estimated $2,777.2 million in 2013 and is expected to reach $3,780.3 million by 2020, at a CAGR of 4.0% from 2015 to 2020. Presently, the acute lymphocytic/lymphoblastic leukemia market is driven by factors such as the increasing incidence rate of ALL cases, development of innovative therapies such as multi-drug regimens, and continuous efforts of pharmaceutical companies to offer superior-quality drugs. Such improved regimens and drugs have shown significant results in the overall survival rate. The overall growth of the acute lymphocytic/lymphoblastic leukemia therapeutics market is largely challenged by the patent expiration of existing drugs. Arranon (nelarabine), a monotherapy drug, lost its patent in February 2013, whereas, Clolar (clofarabine) is due for patent expiration in 2018. Some of the major players in this market include ERYtech Pharma (France), Talon Therapeutic, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Sigma-Tau Pharmaceuticals, Inc. (U.S.), Pfizer, Inc. (U.S.), and Genzyme Corporation (U.S.). Key Topics Covered: Introduction Executive Summary Market Overview Acute Lymphocytic Leukemia Market Dynamics Leukemia Product Market Acute Lymphocytic Leukemia Pipeline Molecules (Phase III) Geographic Analysis Company Profiles (Overview, Financials, Products Portfolio, Growth Strategy, and Developments)* *Details On Financials, Products Portfolio, Growth Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies. Competitive Developments (2008 - 2013) List of Tables (50 Tables) List of Figures (28 Figures) For more information visit http://www.researchandmarkets.com/research/6skk97/acute About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acute Lymphocytic Leukemia Therapeutics Market 2020 Forecasts
M2 - Wed Dec 11, 3:27AM CST
The acute lymphocytic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic leukemia may also occur in adults. The acute lymphocytic leukemia market is segmented into two types-childhood acute lymphocytic leukemia and adult acute lymphocytic leukemia.
Spectrum Pharmaceuticals Launches Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders
Business Wire - Tue Sep 03, 6:00AM CDT
--Two ongoing Phase 3 trials evaluating Marqibo in additional indications.
LQMT, GSAT, TLON and ACTC added to OTC Active Stock Watch List at EPR
ACCESSWIRE - Thu Jul 18, 8:05AM CDT
New York, NY - (ACCESSWIRE) - 07/18/2013 - Equity Profile Report initiates its OTC Active Stock Watch List adding Liquidmetal Technologies Inc. (OTC:LQMT), Globalstar Inc. (OTC:GSAT), Talon Therapeutics, Inc. (OTC:TLON) and Advanced Cell Technology Inc. (OTC:ACTC)
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
GlobeNewswire - Thu Jul 18, 7:00AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that its licensee, Talon Therapeutics, Inc. (OTCBB:TLON), announced that it will be acquired by Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI).
Spectrum Pharmaceuticals Acquires Talon Therapeutics, Inc.
Business Wire - Wed Jul 17, 6:00AM CDT
--Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion is expected to be launched later this year through Spectrum's existing hematology sales force.
Spectrum Pharmaceuticals Acquires Talon Therapeutics
GlobeNewswire - Wed Jul 17, 6:00AM CDT
Talon Therapeutics, Inc. (OTCQB:TLON) today announced that a subsidiary of Spectrum Pharmaceuticals, Inc. (Nasdaq:SPPI) entered into an agreement to purchase approximately 89% of the outstanding shares of Talon (the "Company") directly from the Company's principal stockholders. Spectrum also entered into an agreement with the Company under which the subsidiary of Spectrum will purchase additional shares from the Company that, together with the shares acquired from the Company's principal stockholders, will represent in excess of 90% of the outstanding shares of Talon, and under which Spectrum will acquire the remaining outstanding shares of Company common stock through a "short-form" merger of the subsidiary of Spectrum into the Company. The Company and Spectrum expect that the share purchase and the merger will be completed within one business day.
Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
M2 - Thu Jun 27, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5m9c2h/global_lung) has announced the addition of the "Global Lung Cancer Therapeutics Market 2012-2016" report to their offering. Global Lung Cancer Therapeutics Market To Grow At A CAGR Of 13.26 Percent Over The Period 2012-2016 The Global Lung Cancer Therapeutics Market 2012-2016 report has been prepared based on an in-depth analysis of the market with inputs from industry experts. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''There has been an increase in medical tourism in the APAC region. Patients from all around world are visiting countries such as China and India for treatments. The healthcare facilities in the APAC region are improving, with excellent healthcare providers providing better treatment for diseases such as cancer or any other treatment at a low cost. Thus, the increase in the number of patients coming to China and India for cancer treatment is a growing trend, which is encouraging the he
Talon Therapeutics, Inc. Reports First Quarter 2013 Financial Results
GlobeNewswire - Wed May 15, 4:00PM CDT
Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the three months ended March 31, 2013.
Talon Therapeutics, Inc. Reports Fourth Quarter and Year End 2012 Financial Results
GlobeNewswire - Mon Apr 01, 8:00AM CDT
Talon Therapeutics, Inc., (OTCQB:TLON), today reported financial results for the fourth quarter and year ended December 31, 2012.
Global Leukemia Therapeutics Market 2012-2016: Bristol-Myers Squibb Co., Celgene Corp., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., and Novartis AG. Dominate the Market
M2 - Thu Mar 28, 6:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnhx5c/global_leukemia) has announced the addition of the "Global Leukemia Therapeutics Market 2012-2016" report to their offering. TechNavio's analysts forecast the Global Leukemia Therapeutics market to grow at a CAGR of 10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Leukemia Therapeutics market has also been witnessing an increase in the number of mergers and acquisitions. However, the delay in cancer diagnosis could pose a challenge to the growth of this market. Commenting on the report, an analyst from TechNavio's Healthcare team said: ''There has been increase in the volume of medical tourism in the APAC region. Patients from all around the world are visiting countries such as China and India for various treatments. Healthcare facilities in the APAC region are improving and there is an excellent range of h
Talon Therapeutics to Host a Conference Call to Report 2012 Financial Results and Business Update on April 1, 2013
GlobeNewswire - Tue Mar 19, 8:00AM CDT
Talon Therapeutics, Inc. (OTCQB:TLON) will host a conference call on Monday, April 1, 2013 at 9:00AM PDT, to discuss 2012 financial results and provide a business update.
Talon Therapeutics Announces Review of Strategic Alternatives
GlobeNewswire - Mon Jan 07, 8:00AM CST
Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced that the Board has authorized a review of strategic alternatives. Goldman Sachs has been engaged to provide financial advisory services. The review of strategic alternatives may lead to a possible transaction, including the merger, business combination, or sale of the company.
Talon Therapeutics Appoints Elizabeth Weatherman to Board of Directors
GlobeNewswire - Fri Jan 04, 8:00AM CST
Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced the appointment of Elizabeth (Bess) Weatherman to the Company's Board of Directors. Ms. Weatherman is a Managing Director of Warburg Pincus and leads the firm's investment activity in the healthcare sector. Warburg Pincus is the majority shareholder of Talon.
(0)
(0)Talon Therapeutics Inc (TLON) Stock Research Links
Scroll down for more posts ▼